Drug intelligence / Profile preview

recombinant human proteoglycan 4

Development stage
Phase 2
Lead developer
Lubris Bio
Modality
Recombinant Proteins and Enzymes
Administration
Ophthalmic
01

Overview

Recombinant human proteoglycan 4 (rhPRG4), also known as recombinant human lubricin, is a large, highly glycosylated mucin-like glycoprotein developed by Lubris Bio. It is designed to mimic the function of endogenous lubricin, which is naturally present in the tear film and on the ocular surface to provide boundary lubrication and reduce friction between the eyelid and the cornea. In conditions like Sjögren's syndrome and dry eye disease, lubricin expression is often downregulated, leading to increased mechanical friction and subsequent inflammation. Beyond its mechanical lubricating properties, rhPRG4 has been shown to interact with receptors such as CD44 and Toll-like receptors (TLR2 and TLR4), providing anti-inflammatory effects by inhibiting pro-inflammatory signaling. It is currently being evaluated in clinical trials as a topical ophthalmic solution to alleviate symptoms and signs of ocular surface damage in patients with Sjögren's-related dry eye disease.

Brand names
lubricin recombinant
Other names
recombinant human lubricinlubricinPRG4PRG-4PRG 4
02

Targets

CD44 (CD44 antigen)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on recombinant human proteoglycan 4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human proteoglycan 4.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call